Josep Solà (Aktiia)
Overview
Josep Solà is a noted Swiss researcher and entrepreneur renowned for his contributions to the field of blood pressure monitoring innovation. As a co-founder of Aktiia, a company specializing in non-invasive, cuffless blood pressure monitoring technology, Solà's work focuses on making hypertension detection and management more accessible and efficient. His developments in optical sensing technology have placed him at the forefront of medical technology advancement, particularly in photoplethysmography and its application in digital health.
Recent Developments
Over the past few years, Josep Solà has been instrumental in advancing Aktiia's technological and commercial milestones:
- June 2024: Aktiia received CE mark approval for its non-cuff optical technology, an advancement that allows access to multiple international markets. This development promises to revolutionize blood pressure monitoring by integrating medical-grade systems into everyday consumer gadgets such as smartphones and wearables.
- October 2024: Aktiia announced a breakthrough in blood pressure management through AI application, trained on 11 billion data points, to provide blood pressure readings using just a smartphone camera. This development signifies a shift from traditional hardware-based solutions to more software-centered approaches.
- February 2024: Aktiia raised $30.7 million in a Series B funding round, enabling further research, development, and market expansion. The investment round was participated by prominent investors such as Redalpine and Khosla Ventures.
- July 2024: In collaboration with Lindus Health, Aktiia initiated a clinical trial to validate its optical blood pressure monitoring device's accuracy and continuous monitoring capability.
- 2025: Josep Solà co-authored a study published in "Frontiers in Digital Health" that further explored the applications of PPG signals in assessing blood pressure, highlighting the potential to transform hypertension management with non-invasive methods.
Personal Information
| Attribute | Information |
|---|---|
| Full Name | Josep Solà |
| Born | N/A (Details not publicly available) |
| Nationality | Swiss |
| Occupation | CTO at Aktiia SA |
| Known For | Co-developing cuffless blood pressure monitoring technology |
| Net Worth | N/A |
| Education | Eidgenössische Technische Hochschule Zürich |
Early Life and Education
Josep Solà pursued his higher education at the Eidgenössische Technische Hochschule Zürich, one of Switzerland's premier institutions known for its emphasis on engineering and technology. During these formative years, Solà developed a keen interest in biomedical engineering, which laid the groundwork for his future endeavors in non-invasive monitoring technologies. This academic background, combined with a post-education stint at the Swiss research institution CSEM, solidified his expertise in medical device innovation.
Career and Notable Achievements
Josep Solà embarked on his career focusing on the integration of photoplethysmography in medical diagnostics, specifically targeting blood pressure monitoring:
- 2018: Co-founded Aktiia, focusing on pioneering continuous, cuffless blood pressure monitors.
- Research Publications: Authored comprehensive studies on cuffless BP technology and its field applications, including optical sensing strategies.
- Innovations: Developed methodologies to predict blood pressure using PPG data without traditional cuffs, potentially increasing accessibility and comfort.
- AI Integration: Spearheaded initiatives at Aktiia to use AI in processing vast datasets to improve diagnostic accuracy and device user experience.
Current Work and Impact
As of 2025, Josep Solà continues his role as Chief Technology Officer at Aktiia, where he drives innovation in non-invasive health monitoring solutions. His recent focus on integrating AI with optical sensing technologies stands to redefine conventional methods of hypertension management, facilitating user-friendly, continuous health monitoring compatible with consumer electronics. His work has significant implications for public health, potentially improving early detection and management of hypertension globally.
Conclusion
Josep Solà's contributions to the field of digital health, particularly in blood pressure monitoring technologies, are setting new benchmarks in the industry. By shifting from traditional methods to AI-powered, non-invasive solutions, Solà is not only enhancing the quality and accessibility of hypertension diagnosis and management but also paving the way for future innovations in telehealth and wearable technologies. His work holds promise for substantial advancements in healthcare delivery, making a notable impact on how cardiovascular conditions are managed worldwide.